News
-
-
-
COMMUNIQUÉ DE PRESSE
Jaguar Health Enters into U.S. License Agreement with Future Pak for Crofelemer, Providing up to $38 Million
Jaguar Health, Inc. enters U.S. licensing agreement with Future Pak, LLC for exclusive marketing rights of Mytesi® and Canalevia®-CA1, securing $18M upfront payment and potential $20M in milestone payments -
-
-
COMMUNIQUÉ DE PRESSE
Article About Groundbreaking Results from Study of Jaguar Health's Crofelemer for Treatment of Intestinal Failure Featured in United Arab Emirates Healthcare Publication
Jaguar Health announced groundbreaking results from ongoing proof-of-concept study of crofelemer in pediatric patients with intestinal failure, showing significant reduction of parenteral support (PS) and potential to save lives -
-
-
COMMUNIQUÉ DE PRESSE
Jaguar Health Awarded $240,000 FDA Grant in Support of Canalevia-CA1 for Treatment of Chemotherapy-Induced Diarrhea (CID) in Dogs
Jaguar Health, Inc. receives $240,000 grant from FDA for Canalevia-CA1 study on chemotherapy-induced diarrhea in dogs. Focus on CID treatment effectiveness -
